# TABLE OF CONTENTS

## LIST OF TABLES

## LIST OF FIGURES

## EXECUTIVE SUMMARY AND HIGHLIGHTS

## 1. MARKET

### 1. Definitions and scope

#### 1.1 Imaging

#### 1.1.1 Imaging

#### 1.1.2 Pathology

#### 1.1.3 Health screening

### 1.2 Size

#### 1.2.1 Imaging

#### 1.2.2 Pathology

#### 1.2.3 Genetic testing

### 1.3 Historic growth

#### 1.3.1 Imaging

#### 1.3.1.1 NHS organisations

#### 1.3.2 Pathology

#### 1.3.3 Private hospitals

### 1.4 Segmentation/funding, by payor type

### 1.5 Demand drivers

#### 1.5.1 Impact of Covid

#### 1.5.1.1 The overall impact of Covid on the healthcare system

#### 1.5.1.2 The consequences for diagnostics

#### 1.5.1.3 Covid testing

#### 1.5.1.4 The impact of Covid on waiting lists for diagnostics

#### 1.5.1.5 The other long-term consequences of Covid on diagnostics

### 1.6 Supply

#### 1.6.1 Equipment

#### 1.6.2 Staffing

### 1.7 Operating and investment models

---

LaingBuisson  
Diagnostics, second edition  
iii
1.7.1 Imaging
   1.7.1.1 NHS contracts 53
   1.7.1.2 Private hospital contracts 54
   1.7.1.3 Independent imaging centres 55
   1.7.1.4 High-end screening services 57
1.7.2 Image reporting 57
1.7.3 Pathology 59
   1.7.3.1 NHS joint ventures/full outsourcing 60
   1.7.3.2 Full service private labs 60
   1.7.3.3 Private hospital outsourcing contracts 61
1.7.4 Histology reporting 61
1.7.5 Specialist labs 62

2. POLITICS AND REGULATION 65
2.1 Current regulators and regulation 65
   2.1.1 Care Quality Commission 65
   2.1.2 Health and Safety Executive (HSE) 65
   2.1.3 Ionising Radiation Medical Exposure Regulations (IRMER) 65
   2.1.4 The Quality Standard for Imaging (QSI) 66
   2.1.5 UKAS ISO15189 66
   2.1.6 Medicines and Healthcare Products Regulatory Agency (MHRA) 66
   2.1.7 Human Tissue Authority (HTA) 66
2.2 Royal colleges and professional bodies 66
2.3 Industry associations 67
   2.3.1 British Institute of Radiology 67
   2.3.2 British In Vitro Diagnostics Association (BIVDA) 67
   2.3.3 MedTech Europe 67

3. PAYORS 69
3.1 Payor groups 69
   3.1.1 NHS 69
   3.1.2 Local authorities 69
### Table of Contents

3.1.3 Private hospitals and providers 69  
3.1.4 Private Medical Insurers (PMI) 69  
3.1.5 Self pay but medically referred 70  
3.1.6 Direct to consumer or b2c 70  
3.1.7 Other payer groups 70  
  3.1.7.1 Occupational health 70  
  3.1.7.2 Paternity testing 71  
  3.1.7.3 Judicial testing 71  
  3.1.7.4 Elite sports 71  
3.2.1 NHS 71  
  3.2.1.1 Imaging 71  
  3.2.1.2 Private Medical Insurers (PMI) and self-pay 74  
  3.2.1.3 Pathology 75  
3.2.2 Local authorities 80  
3.2.3 Private providers 80  
  3.2.3.1 Imaging 81  
  3.2.3.2 Pathology 81  
3.2.4 Private Medical Insurers 83  
3.2.5 Self-pay but medically referred 83  
3.2.6 Direct to consumer 83  

4. **MAJOR PROVIDERS** 85  

4.1 Market concentration by segment 85  
  4.1.1 Image generation 85  
  4.1.2 Image reporting 86  
  4.1.3 Pathology laboratory services 87  
  4.1.4 Pathology reporting 87  
4.2 Economies of scale and scope 89  
  4.2.1 Imaging 89  
  4.2.2 Imaging reporting 90  
  4.2.3 Pathology 90  
  4.2.4 Pathology reporting 90
4.3  Major provider profiles

<table>
<thead>
<tr>
<th>Subsection</th>
<th>Company Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.3.1</td>
<td>Image generation service providers</td>
<td></td>
</tr>
<tr>
<td>4.3.1.1</td>
<td>Alliance Medical</td>
<td>91</td>
</tr>
<tr>
<td>4.3.1.2</td>
<td>Diagnostic Healthcare</td>
<td>94</td>
</tr>
<tr>
<td>4.3.1.3</td>
<td>InHealth</td>
<td>97</td>
</tr>
<tr>
<td>4.3.1.4</td>
<td>Medical Imaging Partnership</td>
<td>101</td>
</tr>
<tr>
<td>4.3.1.5</td>
<td>Mediscan</td>
<td>103</td>
</tr>
<tr>
<td>4.3.1.6</td>
<td>Medneo</td>
<td>106</td>
</tr>
<tr>
<td>4.3.2</td>
<td>Image reporting agencies</td>
<td></td>
</tr>
<tr>
<td>4.3.2.1</td>
<td>4Ways</td>
<td>107</td>
</tr>
<tr>
<td>4.3.2.2</td>
<td>DMC Healthcare (fka Dulwich Medical Centre)</td>
<td>110</td>
</tr>
<tr>
<td>4.3.2.3</td>
<td>Everlight Radiology</td>
<td>111</td>
</tr>
<tr>
<td>4.3.2.4</td>
<td>Medica plc</td>
<td>113</td>
</tr>
<tr>
<td>4.3.2.5</td>
<td>Radnet</td>
<td>115</td>
</tr>
<tr>
<td>4.3.2.6</td>
<td>Unilabs plc</td>
<td>116</td>
</tr>
<tr>
<td>4.3.3</td>
<td>Laboratory service providers</td>
<td></td>
</tr>
<tr>
<td>4.3.3.1</td>
<td>Alderly Lighthouse Laboratory</td>
<td>119</td>
</tr>
<tr>
<td>4.3.3.2</td>
<td>Check4Cancer</td>
<td>120</td>
</tr>
<tr>
<td>4.3.3.3</td>
<td>Eurofins Biomnis</td>
<td>121</td>
</tr>
<tr>
<td>4.3.3.4</td>
<td>FlouretiQ</td>
<td>125</td>
</tr>
<tr>
<td>4.3.3.5</td>
<td>London Medical Laboratory</td>
<td>126</td>
</tr>
<tr>
<td>4.3.3.6</td>
<td>Nationwide Pathology</td>
<td>127</td>
</tr>
<tr>
<td>4.3.3.7</td>
<td>Medilims</td>
<td>128</td>
</tr>
<tr>
<td>4.3.3.8</td>
<td>Melio</td>
<td>129</td>
</tr>
<tr>
<td>4.3.3.9</td>
<td>Micropathology</td>
<td>130</td>
</tr>
<tr>
<td>4.3.3.10</td>
<td>Numan</td>
<td>131</td>
</tr>
<tr>
<td>4.3.3.11</td>
<td>Prenetics</td>
<td>132</td>
</tr>
<tr>
<td>4.3.3.12</td>
<td>Serco/Synnovis</td>
<td>133</td>
</tr>
<tr>
<td>4.3.3.13</td>
<td>Sonic Healthcare (through UK subsidiary The Doctors Laboratory)</td>
<td>136</td>
</tr>
<tr>
<td>4.3.3.14</td>
<td>Synlab</td>
<td>137</td>
</tr>
<tr>
<td>4.3.3.15</td>
<td>Thriva</td>
<td>141</td>
</tr>
</tbody>
</table>
4.3.3.16 Truepill 142
4.3.3.17 Xyla Diagnostics 143

4.3.4 Major international diagnostic service companies not currently present in the UK 144
4.3.4.1 Affidea 144
4.3.4.2 Alab 146
4.3.4.3 Amedes 147
4.3.4.4 Canon Medical Systems 150
4.3.4.5 LabCorp 151
4.3.4.6 Limbach Group 156
4.3.4.7 Medicover 157
4.3.4.8 Quest Diagnostics 159

5. KEY SUPPLIERS TO THE MARKET 165
5.1 Major imaging suppliers 165
5.1.1 Canon 165
5.1.2 GE Healthcare 168
5.1.3 Hitachi 174
5.1.4 Philips 176
5.1.5 Siemens 181

5.2 Pathology 186
5.2.1 Major full laboratory/managed equipment service providers 186
5.2.1.1 Abbott 186
5.2.1.2 Beckman Coulter 188
5.2.1.3 Roche 190

5.2.2 Histopathology reporting service providers 194
5.2.2.1 Backlogs (part of HCA Laboratories) 194
5.2.2.2 Cellular Pathology Services 195
5.2.2.3 Diagnexia 196
5.2.2.4 Digital Pathology Partners 197
5.2.2.5 Pathognomics (Cyted) 198
5.2.2.6 Poundbury Cancer Institute 199
5.2.2.7 Source Bioscience

5.2.3 Other significant laboratory suppliers

5.2.3.1 Agilent (niche products including mass spectrometry)

5.2.3.2 Becton Dickinson (sample collection systems, cytology systems, microbiology automation)

5.2.3.3 bioMérieux (Microbiology products)

5.2.3.4 Illumina (genetic sequencing)

5.2.3.5 Oxford Nanopore

5.2.3.6 Roper Technologies

5.2.3.7 Sysmex (haematology products)

5.2.3.8 Thermo Fisher Scientific

5.4 Diagnostic software/IT providers

5.4.1 Citadel Health

5.4.2 Dedalus

5.4.3 Xlab

6. INVESTORS

6.1 Investors involved in the sector and their portfolios

6.2 Overseas quoted groups

6.2.1 Life Healthcare

6.2.2 Sonic Group

6.2.3 Synlab

6.2 Private equity funds and their portfolios

6.2.1 Apax

6.2.2 A.P. Moller Holding

6.2.3 Apposite Capital

6.2.4 Cinven

6.2.5 ECI Partners

6.2.6 Livingbridge

6.2.7 Seneca Partners Home

6.2.8 Synova

6.3 Major International diagnostic service groups not currently involved in the
UK diagnostic market

6.3.1 Affidea

6.3.2 Alab

6.3.3 Amedes

6.3.4 LabCorp

6.3.5 Medicover

6.3.6 Quest

6.4 Exits, entries, acquisitions and other key events

7. MARKET POTENTIAL

7.1 Future need, prospects

7.2 New technology

7.2.1 Genomic testing

7.2.1.1 BGI Genomics (China)

7.2.1.2 Centogene

7.2.1.3 Exact Sciences

7.2.1.4 Foundation Medicine

7.2.1.5 Grail

7.2.1.6 Guardant

7.2.1.7 Helix

7.2.1.8 Illumina

7.2.1.9 Myriad Genetics

7.2.1.10 Natera

7.2.1.11 Sema4

7.2.1.12 Agenda

7.2.1.13 Biotheranostics

7.2.1.14 Exosome Diagnostics

7.2.1.15 Inivata

7.2.1.16 MDx Healthcare

7.2.1.17 MLL (Munich Leukaemia Laboratory)

7.2.1.18 Nanostring Technologies

7.2.1.19 NIMGenetics Spain
7.2.1.20 Omniseq 252
7.2.1.21 Oncologica UK 252
7.2.1.22 OncoDNA 253
7.2.1.23 Oxford Cancer Biomarkers (OCB) 253
7.2.1.24 Personal Genome Diagnostics 253
7.2.1.25 Veracyte 253
7.2.1.26 Eurofins 254
7.2.1.27 LabCorp (US) 254
7.2.1.28 Quest (US) 254
7.2.1.29 Sonic (TDL parent) 254
7.2.1.30 Source Bioscience 255
7.2.1.31 Synlab 255
7.2.2 Digital histology 255
7.2.3 Artificial Intelligence (AI) 256
  7.2.3.1 Aidance 256
  7.2.3.2 Behold AI 257
  7.2.3.3 Google 257
  7.2.3.4 Kheiron Medical 257
  7.2.3.5 Qure 257
  7.2.3.6 Signify Research 258
  7.2.3.7 Ibex 258
7.2.4 Other innovative technology 258
  7.2.4.1 Healthy.io 258
  7.2.4.2 Vitestro Vitestro 259
7.3 International comparisons 259
7.4 Market volume, pricing and value forecasts 269
  7.4.1 Demographics 270
  7.4.2 Macro economics 270
  7.4.3 NHS policy/post-Covid recovery 270
  7.4.4 Developments in AI and medical technology 270
  7.4.5 Consumerism 270
Table of Contents

7.5.6 Employer attitude to benefits/PMI 271
7.5.7 Medical practice 271
7.6 Conclusions 271

APPENDIX 1. GLOSSARY 273
APPENDIX 2. REGULATORS 277
APPENDIX 3. TRADE BODIES AND ASSOCIATIONS 279
Healthcare Markets UK is the leading journal covering the UK independent healthcare sector. Drawing upon LaingBuisson’s unique data, the title combines high-quality journalism with in-depth analysis and contributions from key industry associations and sector experts. Digital and print subscriptions include access to an online archive dating back to 1998.

For further information on these titles visit laingbuissonnews.com where you can sign up for a trial, or contact our account managers on sales@laingbuisson.com or +44 (0)20 7841 0045

**Independent. Intelligent. Insightful.**

**Ten print editions** - delivered through the year

**News insight** - taking stories beyond the headlines

**In depth features** - written by authors with a deep understanding of the markets

**Interviews** - with leading healthcare figures

**Unique data tables** - presenting LaingBuisson figures on market sizes

**Special supplements** - including roundtable reports, cost surveys, infographic posters

**Online archive** - news and features dating back well over a decade

**News e-alerts** - delivered to your inbox

**Additional subscriber benefits**

**Early registration window** for LaingBuisson conferences and seminars, with fixed ‘early bird’ rate

**5% discount** on all additional LaingBuisson product or event purchases made throughout your subscription

**Subscribe now**

Subscribe to a single printed hard copy title for just £499 a year, or upgrade to receive print and digital copies for £749, or take out a subscription to both Healthcare Markets and Care Markets and pay just £749 for print and £999 for the digital package.

Company-wide subscription packages also available including multiple print copies and online subscription accounts - call to discuss prices.
**LIST OF TABLES**

<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>ES1</td>
<td>‘Wholesale’ imaging market, £m, UK, 2021 (cost to hospitals of providing/outsourcing services)</td>
<td>2</td>
</tr>
<tr>
<td>ES2</td>
<td>‘Wholesale’ pathology market, £m, UK, 2021 (cost to hospitals of providing/outsourcing services)</td>
<td>3</td>
</tr>
<tr>
<td>1.1</td>
<td>National screening programmes, England, 2020/21</td>
<td>16</td>
</tr>
<tr>
<td>1.2</td>
<td>Diagnostic market, £m, UK, 2021</td>
<td>17</td>
</tr>
<tr>
<td>1.3</td>
<td>Volume of images/scans (000s) by modality, UK, 2021 (est.)</td>
<td>18</td>
</tr>
<tr>
<td>1.4</td>
<td>Proportion of images generated by in-house vs. outsourced to imaging companies, 2021</td>
<td>19</td>
</tr>
<tr>
<td>1.5</td>
<td>Reporting of NHS images (000s) for NHS organisations, 2021/22 (est.)</td>
<td>20</td>
</tr>
<tr>
<td>1.6</td>
<td>‘Wholesale’ volume and value of image generation market, 2021</td>
<td>21</td>
</tr>
<tr>
<td>1.7</td>
<td>Reporting of images (000s) market value, 2021</td>
<td>22</td>
</tr>
<tr>
<td>1.8</td>
<td>Consultant radiologist primary and secondary interest, 2018</td>
<td>23</td>
</tr>
<tr>
<td>1.9</td>
<td>NHS and private pathology test volumes, number of tests undertaken in laboratories (millions), UK, 2021/22</td>
<td>24</td>
</tr>
<tr>
<td>1.10a</td>
<td>Number of NHS tests (millions) split between direct access (GP requested) and hospital, UK, 2021/22 (est.)</td>
<td>24</td>
</tr>
<tr>
<td>1.10b</td>
<td>NHS pathology test volumes (millions) and cost, £m, 2021 (est.)</td>
<td>25</td>
</tr>
<tr>
<td>1.11</td>
<td>NHS and private pathology values, cost/value of tests, £m, UK, 2021 (est.)</td>
<td>26</td>
</tr>
<tr>
<td>1.12</td>
<td>NHS lab costs (including outsourced), £m, and staffing, 2021</td>
<td>27</td>
</tr>
<tr>
<td>1.13</td>
<td>NHS biochemistry tests, UK, 2021 (est.)</td>
<td>27</td>
</tr>
<tr>
<td>1.14</td>
<td>NHS haematology tests, UK, 2021</td>
<td>29</td>
</tr>
<tr>
<td>1.15</td>
<td>NHS immunology tests, UK, 2021</td>
<td>29</td>
</tr>
<tr>
<td>1.16</td>
<td>NHS microbiology tests, UK, 2021</td>
<td>30</td>
</tr>
<tr>
<td>1.17</td>
<td>NHS cellular pathology tests, UK, 2021</td>
<td>30</td>
</tr>
<tr>
<td>1.18</td>
<td>NHS organisations scans (000s) by modality, UK, 2012‒2021</td>
<td>32</td>
</tr>
<tr>
<td>1.19</td>
<td>Private hospital/clinic image generation (000s) by modality, UK, 2012‒2021</td>
<td>34</td>
</tr>
<tr>
<td>1.20</td>
<td>NHS radiology tariffs (examples of high volume images), £ nominal, 2012/13‒2020/21</td>
<td>35</td>
</tr>
<tr>
<td>1.21a</td>
<td>NHS organisations reporting by modality, 000s, UK, 2012‒2021</td>
<td>36</td>
</tr>
<tr>
<td>1.21b</td>
<td>NHS organisation average cost of reporting per scan by modality, £ nominal, 2012‒2021</td>
<td>36</td>
</tr>
<tr>
<td>1.21c</td>
<td>NHS organisation value of reporting per scan by modality, £m (nominal), 2012‒2021</td>
<td>37</td>
</tr>
<tr>
<td>1.22</td>
<td>Private hospitals/clinics and PPUs, reporting by modality, 000s, UK, 2012‒21</td>
<td>37</td>
</tr>
<tr>
<td>1.23</td>
<td>NHS hospital pathology test volumes, millions, UK, 2012‒21</td>
<td>38</td>
</tr>
<tr>
<td>1.24</td>
<td>Private hospital/clinic pathology test volumes, millions, UK, 2012‒21</td>
<td>39</td>
</tr>
</tbody>
</table>
# List of Tables

<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table 1.25</td>
<td>Retail market, by payor, £m, 2021</td>
<td>41</td>
</tr>
<tr>
<td>Table 1.26</td>
<td>Self-pay rates in private hospitals and clinics, £ per scan, 2021</td>
<td>42</td>
</tr>
<tr>
<td>Table 1.27</td>
<td>Typical imaging rates paid by PMI to private hospitals, £ per scan, 2021</td>
<td>42</td>
</tr>
<tr>
<td>Table 1.28</td>
<td>Typical pathology rates paid by PMI to private hospitals, £ per test, 2021</td>
<td>43</td>
</tr>
<tr>
<td>Table 1.29</td>
<td>Covid testing, million tests per quarter, UK, 2020–2022</td>
<td>46</td>
</tr>
<tr>
<td>Table 1.30</td>
<td>Average tests per day, 000s, UK, 2020–2022</td>
<td>46</td>
</tr>
<tr>
<td>Table 1.31</td>
<td>NHS England patients waiting over 13 weeks for diagnostic tests, UK, 2018–2022</td>
<td>48</td>
</tr>
<tr>
<td>Table 1.32</td>
<td>Radiologists employed in the NHS, UK, 2014–2021</td>
<td>51</td>
</tr>
<tr>
<td>Table 3.1</td>
<td>Medica reporting prices, £ nominal/scan, 2013–2018</td>
<td>72</td>
</tr>
<tr>
<td>Table 4.1</td>
<td>Image generation market shares, £m, 2021 (est.)</td>
<td>85</td>
</tr>
<tr>
<td>Table 4.2</td>
<td>Image generation market, estimated market shares, %, 2021 (est.)</td>
<td>85</td>
</tr>
<tr>
<td>Table 4.3</td>
<td>Image reporting market shares, £m and market share %, 2021</td>
<td>86</td>
</tr>
<tr>
<td>Table 4.4</td>
<td>Pathology laboratory services revenues by segment, £m, 2021</td>
<td>87</td>
</tr>
<tr>
<td>Table 4.5</td>
<td>Laboratory company and subsidiary/JV company accounts, £000s, 2018–21</td>
<td>88</td>
</tr>
<tr>
<td>Table 4.6</td>
<td>Histopathology reporting market shares, £m and %, 2021</td>
<td>89</td>
</tr>
<tr>
<td>Table 6.1</td>
<td>Diagnostic market key events, 2007–2022</td>
<td>242</td>
</tr>
<tr>
<td>Table 7.1a</td>
<td>MRI scans per 1,000 population (ranked by 2019 to avoid Covid distortions)</td>
<td>261</td>
</tr>
<tr>
<td>Table 7.1b</td>
<td>MRI scanners per million population (ranked by 2019 to avoid Covid distortions)</td>
<td>262</td>
</tr>
<tr>
<td>Table 7.2a</td>
<td>CT scans per 100 population (ranked by 2019 to avoid Covid distortions)</td>
<td>264</td>
</tr>
<tr>
<td>Table 7.2b</td>
<td>CT scanners per million population (ranked by 2019 to avoid Covid distortions)</td>
<td>265</td>
</tr>
<tr>
<td>Table 7.3</td>
<td>PET CT Scans per 1,000 population (ranked by 2017)</td>
<td>267</td>
</tr>
<tr>
<td>Table 7.4</td>
<td>Imaging equipment utilisation, ranked by MRI</td>
<td>268</td>
</tr>
<tr>
<td>Table 7.5</td>
<td>Diagnostic consultants per 100,000 citizens</td>
<td>269</td>
</tr>
</tbody>
</table>
LIST OF FIGURES

Figure ES1  Imaging market, UK  
Figure ES2  Pathology market, UK  
Figure 1.1  NHS lab costs (including outsourcing), UK, 2021 (est.)  
Figure 1.2  NHS organisations scans (000s) per modality, UK, 2021/22  
Figure 1.3  Private hospital/clinic image generation (000s) by modality, UK, 2021  
Figure 3.1  Use of commercial image reporting companies by NHS organisations, 2021/22 (and 2017/18)  
Figure 3.2  Spend with consultants and commercial reporting companies, 2021/22 (and 2017/18)  
Figure 3.3  NHS England CCG methods of paying for GP Direct Access pathology, 2021/22 (and 2017/18)  
Figure 3.4  Models used by Trusts for reporting excess histology demand, 2021/22 (and 2017/18)  
Figure 3.4b  ...of those trusts using commercial companies, their spending in the last year, 2021/22 (and 2017/18)  
Figure 4.1  Image reporting market, £m, 2021  
Figure 7.1a  MRI scans per 1,000 population, 2020  
Figure 7.1b  MRI scans per million population, 2020  
Figure 7.2a  CT scans per 100 population, 2020  
Figure 7.2b  CT scanners per million population, 2020  
Figure 7.3  PET CT Scans per 1,000 population, 2017
Do you want to understand the global healthcare market?

Healthcare Markets International, the latest journal from business intelligence provider LaingBuisson, delivers comprehensive, reliable and independent reporting on the full range of acute and primary healthcare services markets operating around the world. This digital journal covers medical and surgical hospitals and clinics, psychiatric hospitals, fertility, dentistry, primary healthcare and temporary/flexible staffing. Embracing the latest business activities across the healthcare sector, HMi delivers interviews with leading names in the sector, in-depth features and business news coverage, providing invaluable insight and analysis.

SUBSCRIBE NOW

An annual digital subscription is just £749 and provides you with online access to the latest market intelligence, ten PDF issues and a subscription to the International Medical Travel Journal.

To find out more visit www.laingbuissonnews.com

📞 +44 (0)20 7841 0045
✉️ sales@laingbuisson.com
🌐 laingbuissonnews.com

REQUEST YOUR FREE TRIAL TODAY